ChromaDex obtains waiver of ~$3.5M in accrued royalties from Dartmouth contingent on appeal bond in Elysium case

Niagen Bioscience, Inc.

Dartmouth waives ~$3.5M in accrued unpaid royalties, license fees, and maintenance expenses under exclusive license agreements.
Waiver contingent on ChromaDex securing an Appeal Bond for fee judgment in Delaware patent infringement case against Elysium Health.
ChromaDex executed the Appeal Bond as of December 3, 2024; plans to move to stay execution of fee judgment pending appeal.
No further royalties or payments will be owed to Dartmouth for the licensed patents after effective date of Supplemental Agreement.
Supplemental Agreement supplements prior exclusive license agreements from 2012 and 2014 for Dartmouth-owned U.S. patents.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.